Diabetes insipidus
Desmopressin Acetate sublingual tablet is indicated for the treatment of-
- Primary Nocturnal Enuresis
- Nocturia and
- Central Diabetes Insipidus
Upon binding of desmopressin to V2 receptors in the basolateral membrane of the cells of the distal tubule and collecting ducts of the nephron, adenylyl cyclase is stimulated. The resulting intracellular cascades in the collecting duct lead to increased rate of insertion of water channels, called aquaporins, into the lumenal membrane and enhanced the permeability of the membrane to water.
Post-hypophysectomy polyuria/polydipsia: The dose of Desmopressin Acetate Melt should be controlled by measurement of urine osmolality.
Lactation: Results from analyses of milk from nursing mothers receiving high dose desmopressin (300 micrograms intranasally) indicate that the amounts of desmopressin that may be transferred to the child are considerably less than the amounts required to influence diuresis.
Care should be taken with patients who have reduced renal function and/or cardiovascular disease. In chronic renal disease the antidiuretic effect of Desmopressin Acetate Melt would be less than normal. Precautions to prevent fluid overload must be taken in:
- conditions characterised by fluid and/or electrolyte imbalance.
- patients at risk for increased intracranial pressure.